Commodore Capital Lp
Institutional manager — quarterly 13F holdings, Q ending 2026-03-31
Reported value
$1.73B
Q ending 2026-03-31
Prior quarter
$1.50B
Q ending 2025-12-31
Change
+15.1% QoQ · +27.4% YoY
Positions
36
reported holdings
Largest positions
All 36 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
| Holding | Ticker | Type | Value ▼ | Shares |
|---|---|---|---|---|
| Relay Therapeutics Inc | RLAY | Shares | $169.2M | 17.0M |
| Alkermes Plc | Shares | $148.5M | 4.2M | |
| Enliven Therapeutics Inc | ELVN | Shares | $128.4M | 3.3M |
| Cogent Biosciences Inc | COGT | Shares | $111.2M | 2.9M |
| Spyre Therapeutics Inc | SYRE | Shares | $96.5M | 1.9M |
| Tyra Biosciences Inc | TYRA | Shares | $94.8M | 2.5M |
| Celldex Therapeutics Inc New | CLDX | Shares | $85.5M | 2.7M |
| Nuvalent Inc | 5AX | Shares | $85.4M | 834K |
| Amylyx Pharmaceuticals Inc | AMLX | Shares | $78.5M | 5.7M |
| Kymera Therapeutics Inc | KYMR | Shares | $62.5M | 750K |
| Alto Neuroscience Inc | ANRO | Shares | $61.2M | 2.7M |
| Pharvaris N V | Shares | $54.2M | 1.9M | |
| Erasca Inc | ERAS | Shares | $51.4M | 3.2M |
| Damora Therapeutics Inc | DMRA | Shares | $50.2M | 1.9M |
| Xenon Pharmaceuticals Inc | XENE | Shares | $48.0M | 825K |
| Definium Therapeutics Inc | DFTX | Shares | $37.8M | 2.0M |
| Lb Pharmaceuticals Inc | LBRX | Shares | $37.0M | 1.5M |
| Eyepoint Inc | EYPT | Shares | $36.4M | 2.8M |
| Nurix Therapeutics Inc | NRIX | Shares | $35.3M | 2.3M |
| Corvus Pharmaceuticals Inc | CRVS | Shares | $33.0M | 2.3M |
| Assembly Biosciences Inc | ASMB | Shares | $27.8M | 1.0M |
| Perspective Therapeutics Inc | CATX | Shares | $26.4M | 6.3M |
| Soleno Therapeutics Inc | SLNOEUR | Shares | $21.8M | 652K |
| Ocular Therapeutix Inc | OCUL | Shares | $21.8M | 2.6M |
| Century Therapeutics Inc | IPSC | Shares | $19.7M | 8.7M |
| Zura Bio Ltd | Shares | $19.3M | 3.3M | |
| Sab Biotherapeutics Inc | SABS | Shares | $16.9M | 4.4M |
| Palisade Bio Inc | PALI | Shares | $12.6M | 7.2M |
| Karyopharm Therapeutics Inc | KPTI | Shares | $10.9M | 1.9M |
| Inhibikase Therapeutics Inc | IKT | Shares | $9.1M | 5.4M |
| An2 Therapeutics Inc | ANTX | Shares | $8.0M | 2.3M |
| Pepgen Inc | PEPG | Shares | $7.9M | 4.5M |
| Avalo Therapeutics Inc | AVTX | Shares | $7.2M | 483K |
| Helix Acquisition Corp Iii | Shares | $5.1M | 500K | |
| Leonabio Inc | LONA | Shares | $4.8M | 464K |
| Relmada Therapeutics Inc | RLMD | Shares | $4.4M | 634K |
Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.